The week's throughline: causation and the warning label
If one thread ran through the dockets this week, it was causation, and specifically the warning label. A federal appeals court closed the first bellwether in the infant-formula litigation on warning-causation grounds. A mass-tort settlement in the Depo-Provera program moved toward finalization while a general-causation hearing still loomed over the cases the deal will not reach. A rideshare assault verdict put a number on a theory the defense spent years calling unprovable. And a discovery order in the hair-relaxer docket showed that courts are done letting settlement talk freeze fact development. None of these is a quiet housekeeping order. Each tells plaintiff firms something concrete about where the next fight will be fought.
The Seventh Circuit hardens the NEC warning wall
The most consequential ruling of the week came out of the preterm-infant-formula litigation. The Seventh Circuit affirmed summary judgment for the manufacturer in the first bellwether, holding that the plaintiff had not shown that a stronger warning would have prevented her child's death from necrotizing enterocolitis. The court did not reject the science of the claim or the theory that cow's-milk-based formula carries an NEC risk for premature infants. It rejected the causal link between the alleged warning defect and the specific outcome, reasoning that the prescribing and feeding decisions in a neonatal intensive care unit are driven by clinicians who already understand the risk.
That is the learned-intermediary problem in a new setting, and it should recalibrate how these cases are worked up. A bellwether loss on warning causation does not end the broader litigation, and a Similac bellwether was on the calendar for later in the month, but it tells plaintiff counsel that the design and manufacturing theories, not the warning theory, may carry the heavier load in the NEC docket going forward. Firms carrying NEC inventory should be stress-testing every file for proof that a different label would have changed a NICU clinician's decision, because the appellate court just signaled that a general risk warning is not enough.
The practical takeaway is a workup change, not a retreat. Warning-causation proof in a NICU case has to connect a specific alternative label to a specific clinical decision, and that is hard when the treating neonatologist already knew the risk and made a judgment call with an informed family. Plaintiff firms that anchored their NEC theory in failure-to-warn should be moving weight onto design and manufacturing defect, and onto whether a safer formulation or a human-milk-based alternative was feasible and available. The appellate ruling does not say the products are safe. It says the warning path, standing alone, may not carry the causal burden. Our product-liability coverage has tracked the NEC bellwethers closely, and this is the first appellate word that the warning path is narrower than plaintiffs hoped.
Depo-Provera moves toward a deal, but the science hearing still matters
In the Depo-Provera meningioma litigation, the parties continued down the path toward a global resolution. The court confirmed earlier in the summer that the manufacturer and plaintiffs' leadership reached an agreement in principle covering eligible cases in the multidistrict litigation, with no admitted liability and no disclosed financial terms, and with state-court cases expressly left out. This week the practical message was that the settlement framework does not moot the general-causation science. The court kept the causation hearing live, and for good reason: a global agreement in principle does not resolve every case, and a general-causation ruling still governs the claims that fall outside or opt out of the framework.
For firms with Depo-Provera clients, the sequencing is the story. An agreement in principle is not a claims process, eligibility criteria and compensation values remain unannounced, and a general-causation ruling can still reshape the leverage of anyone deciding whether to participate. With more than 5,800 cases consolidated, the difference between a favorable and an unfavorable science ruling is the difference between a settlement that clears the inventory and one that leaves a large tail of contested claims.
State-court exposure is the other half of the picture. The federal agreement expressly leaves state cases untouched, which means firms with meningioma clients in state venues are not automatically swept into the framework and may find their leverage tied to how the federal causation ruling is received in their own courts. Coordinating a client's position across a federal deal and a state docket is the kind of decision that has to be made deliberately, not by default. The lien and disbursement mechanics of a program this size will be their own project once terms land, a subject our lien-resolution reporting will return to when the numbers are public.
Hair-relaxer discovery reopens
In the hair-relaxer litigation pending in the Northern District of Illinois, the court lifted the discovery stay as to a group of defendants after concluding that ongoing settlement talks did not justify keeping the case paused. The order is procedural, but its effect is real: discovery resuming against the so-called second-wave defendants moves the litigation off the settlement-only track and back toward contested fact development. For plaintiff firms, that means document and deposition work restarts, and the leverage that comes from a live discovery schedule returns to the table.
The pattern is worth noting because it recurs across mass torts this year. Courts are increasingly unwilling to let open-ended settlement discussions freeze discovery indefinitely, and a stay premised on a deal that has not materialized is vulnerable to exactly this kind of order. Firms that treated the stay as a reason to slow their own workups may find themselves behind when the schedule snaps back.
The rideshare bellwether puts a number on the theory
On the auto and rideshare side, the first federal bellwether in the rideshare sexual-assault litigation produced a compensatory award reported at $8.5 million, in a trial where the company's own product executive conceded under oath that the platform had not done enough to prevent assaults. A single bellwether does not set a settlement value, and the next federal trial was already set for the fall, with jury selection scheduled for mid-September. But an admission like that, on the record, is the kind of fact that reprices an entire inventory.
The doctrinal fight underneath the verdict, whether a platform owes a non-delegable duty for the safety of the rides it brokers, is the one plaintiff firms have been building toward for two years. A compensatory verdict, even a modest one by mass-tort standards, tells defense-side risk managers that juries will accept the theory. Expect the September trial to be watched less for its number than for whether it confirms the pattern.
There is a lien and coordination footnote here too. Sexual-assault recoveries in the rideshare docket frequently involve mental-health treatment, and the reimbursement and privacy questions around that care are more delicate than in an ordinary auto file. Firms building these cases should be thinking about the record and the recovery accounting from intake, not at disbursement.
The backdrop: talc and Camp Lejeune keep paying
Behind the week's new developments, the two largest resolutions of the year kept grinding forward. Johnson & Johnson's $5.5 billion talc settlement, announced late in July to resolve tens of thousands of ovarian-cancer claims, continued to draw firm-by-firm participation decisions, with the deal conditioned on lead firms representing the overwhelming majority of claims signing on. And the Camp Lejeune program continued its slow payout, with settlement offers reported past $960 million and payments past $800 million even as hundreds of thousands of administrative claims remained unresolved. For firms with clients in either program, the practical questions are the same they have been all summer: whether to participate, how offsets and liens will be handled, and how long the client will actually wait for money.
These offset and coordination questions are not incidental to the settlements; they often determine the client's net. The interaction between a federal program payment and other recovery claims is precisely where value leaks, and it is a recurring subject in our med-mal and healthcare-recovery reporting as much as in the lien practice.
What to take into next week
The connective tissue this week was proof, not politics. An appellate court told the formula plaintiffs that a warning theory needs a causal bridge to a clinician's decision. A settling defendant in Depo-Provera reminded everyone that a deal in principle is not a check, and that the science ruling still matters for the tail. A discovery order in the hair-relaxer docket showed that courts will not hold cases in stasis for a settlement that has not closed. And a rideshare jury showed that a theory the defense called speculative can produce a verdict. For plaintiff firms, the lesson is old and unglamorous: the case is built on causation and the record, and the firms working those elements now are the ones positioned when the settlements and the science rulings land.